CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

The advent of chimeric antigen receptor (CAR) T cell therapy has resulted in unprecedented
long-term clearance of relapse/refractory hematological malignancies in both pediatric and …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Metastasis to lymph nodes (LNs) is a common feature of disease progression in most solid
organ malignancies. Consequently, LN biopsy and lymphadenectomy are common clinical …

More than half of the patients treated with CD19-targeted chimeric antigen receptor (CAR) T-
cell immunotherapy for large B-cell lymphoma (LBCL) do not achieve durable remission …

Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in
mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd …

Early in solid tumor development, antigens are presented in tumor-draining lymph nodes
(tdLNs), a process that is necessary to set up immune surveillance. Recent evidence …

Regionalized immune surveillance relies on the concerted efforts of diverse memory T cell
populations. Of these, tissue-resident memory T (TRM) cells are strategically positioned in …